Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
FDA Limits Regulation of Wearable Devices and Wellness Software, Boosting Health Tech Industry 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Newmont Goldcorp Expects Lower Q1 2026 Gold Output After Western Australia Bushfire 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Embraer Boosts Aircraft Deliveries in Q4 2025, Signaling Strong Growth Into 2026 
SOUTH SAN FRANCISCO, Calif., April 05, 2016 -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 9:20 AM ET at the Westin Grand Central Hotel in New York, NY.
Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics retains the right to develop and commercialize tirasemtiv. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics’ specified development and commercialization participation rights. For additional information about Cytokinetics, visit www.cytokinetics.com.
Contact: Cytokinetics Diane Weiser Vice President, Corporate Communications, Investor Relations (650) 624-3060
